GNH USA

Europe — EMA

Miglustat Accord

GNH USA supplies Miglustat Accord (Miglustat), a substrate reduction therapy for Gaucher disease type 1 and Niemann-Pick disease type C. Request a quote.

Miglustat

Request sourcing

1
Pack/s

What is Miglustat?

Miglustat, the active ingredient in Miglustat Accord, is an iminosugar (glucosylceramide synthase inhibitor) presented as an oral formulation for oral use. It is employed in the management of Gaucher disease type 1 and Niemann‑Pick disease type C, reducing pathological substrate accumulation in affected patients.

GNH USA supplies Miglustat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

What is Miglustat used for?

Miglustat is used as a substrate reduction therapy targeting glycosphingolipid accumulation in lysosomal storage disorders. - Gaucher disease type 1: reduces spleen and liver volume and improves hematologic parameters. - Niemann‑Pick disease type C: helps stabilize neurological function and slow disease progression. - Lysosomal storage disorder management: decreases overall glycosphingolipid storage, supporting organ function.

What are the side effects of Miglustat?

Miglustat may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools. - Nausea: feeling of sickness. - Weight loss: unintended reduction in body weight.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas requiring medical attention. - Severe hypersensitivity: rash, swelling, or anaphylaxis. - Elevated liver enzymes: potential liver injury indicated by laboratory tests.

What precautions apply to Miglustat?

When prescribing Miglustat, clinicians should observe several precautionary measures to ensure patient safety. - Monitor liver function: perform baseline and periodic hepatic enzyme tests. - Assess renal function: evaluate creatinine clearance before and during therapy. - Evaluate gastrointestinal tolerance: watch for persistent diarrhea or vomiting. - Review concomitant medications: avoid drugs that may increase toxicity. - Avoid use in patients with known hypersensitivity to miglustat. - Store at room temperature: keep in the original pack, protect from moisture.

What does Miglustat interact with?

Miglustat can interact with other medicines, requiring attention to the level of interaction.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin): may markedly reduce miglustat exposure. - Co‑administration with other substrate reduction agents: increases risk of overlapping toxicity.

Moderate Interactions (Monitor Closely): - Oral contraceptives: miglustat may lower hormonal efficacy, consider alternative methods. - Warfarin: monitor INR values for potential anticoagulant effect changes. - Statins: observe for signs of muscle toxicity or elevated CK levels.

Frequently asked questions

What is Miglustat Accord used for?+
Miglustat Accord contains miglustat, an oral substrate reduction therapy indicated for the treatment of Gaucher disease type 1 and Niemann‑Pick disease type C. By lowering the synthesis of glycosphingolipids, it helps reduce organ enlargement, improve blood parameters, and slow neurological decline in these lysosomal storage disorders. The medication is prescribed by specialists familiar with metabolic diseases.
How does miglustat work?+
Miglustat inhibits the enzyme glucosylceramide synthase, the first step in the biosynthesis of glycosphingolipids. Blocking this pathway decreases the production of glucosylceramide and related complex lipids, which accumulate in lysosomal storage diseases. The resulting reduction in substrate load lessens cellular dysfunction and organ damage associated with Gaucher disease type 1 and Niemann‑Pick disease type C.
What is the usual dose of miglustat?+
The dosage of Miglustat Accord is individualized by the prescribing physician based on the patient’s age, weight, disease severity, and renal function. The prescriber determines the appropriate strength and dosing schedule, and adjustments may be made during therapy according to clinical response and tolerability. Patients should follow the exact regimen provided on the prescription label.
Is miglustat safe during pregnancy or breastfeeding?+
Safety data for miglustat in pregnancy and lactation are limited, and the product’s pregnancy category is not established. It should only be used if the potential benefit justifies any possible risk to the fetus. Breastfeeding mothers should discuss potential exposure with their healthcare provider, as miglustat may be excreted in breast milk.
How do I order Miglustat Accord from GNH USA?+
To request Miglustat Accord, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, and will ask for trade or institutional credentials. The sales team then provides pricing, availability, shipping details—including any temperature‑controlled logistics—and assists with import documentation.
How does miglustat compare with the main alternative therapy?+
The primary alternative for Gaucher disease type 1 is enzyme replacement therapy (ERT), which supplies recombinant glucocerebrosidase. Miglustat, as a substrate reduction therapy, works upstream by decreasing lipid synthesis rather than replacing the missing enzyme. ERT typically requires intravenous infusions, whereas miglustat is an oral tablet, offering convenience but with a different safety profile and efficacy spectrum.
What are the storage and handling requirements for Miglustat Accord?+
Miglustat Accord should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date. No refrigeration is required for this oral formulation.
How is Miglustat Accord administered?+
Miglustat Accord is taken orally, usually with food or a meal to lessen gastrointestinal discomfort. The tablets are swallowed whole with a glass of water and should be taken at the times prescribed by the healthcare professional. Patients should not crush, chew, or split the tablets unless specifically instructed.
What are the most serious risks associated with miglustat?+
The most serious adverse events reported with miglustat include pancreatitis, severe hypersensitivity reactions such as rash or anaphylaxis, and significant elevations in liver enzymes indicating potential hepatic injury. Prompt medical evaluation is required if patients experience persistent abdominal pain, jaundice, unexplained fever, or signs of an allergic reaction.
Who should not use Miglustat Accord?+
Miglustat Accord is contraindicated in individuals with a known hypersensitivity to miglustat or any of its excipients. Caution is advised for patients with severe renal or hepatic impairment, and it should be avoided in those with active gastrointestinal disease that could be worsened by the medication. A qualified prescriber must assess suitability before initiating therapy.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Miglustat
Route
Oral Use
Manufacturer
Accord Healthcare Polska Sp. Z O.O.
Origin
EU

Related products

Miglustat 100 mg/1

Miglustat 100 mg/1

Miglustat · 100 mg

Miglustat
CAPSULE
CoTherix, Inc.
USA
Zavesca 100 mg

Zavesca 100 mg

Miglustat · 100 MG

Zavesca
CAPSULE
JANSSEN INC
CANADA
Sandoz Miglustat 100 mg

Sandoz Miglustat 100 mg

Miglustat · 100 MG

Sandoz Miglustat
CAPSULE
SANDOZ CANADA INCORPORATED
CANADA
Miglustat Accord

Miglustat Accord

Miglustat

Accord Healthcare Limited
EU